Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Victor L. Serebruany"'
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year
Autor:
Victor L. Serebruany, Jean-Francois Tanguay, Milana L. Gurvich, Thomas A. Marciniak, Dan Atar
Publikováno v:
The American Journal of Medicine. 136:484-488
Publikováno v:
The American Journal of Medicine. 133:347-351
Background Ivabradine, a heart rate-slowing drug used to treat heart failure and (in Europe) angina, had varying impacts upon cardiovascular events in its 3 large outcome trials. Food and Drug Administration (FDA) analyses may explain the reasons for
Autor:
Kyungil Park, Victor L. Serebruany, So Yeon Kim, Young Dae Kim, Jong Seong Park, Tae Ho Park, Moo Hyun Kim, Young Rak Cho, K M Lee, Soo Jin Kim
Publikováno v:
Cardiovascular Revascularization Medicine. 19:237-240
Background Mood disorders, depression, and loneliness are established risk factors for thrombotic occlusions. Social relationships in general, and marital status in particular may play a role in predicting cardiovascular outcomes and survival after S
Publikováno v:
Thrombosis Research. 195:72-73
Autor:
Jong Sung Park, Long Zhe Guo, Victor L. Serebruany, Moo Hyun Kim, Tae Ho Park, Cai De Jin, Michael S. Lee, Young Rak Cho, Eun-Seok Shin, Soe Hee Ann, Kyungil Park
Publikováno v:
International Journal of Cardiology. 222:639-644
The impact of thienopyridine reloading on clinical outcomes, and residual high platelet reactivity (HPR) is unclear. We sought to compare the HRP-related effect of prasugrel and clopidogrel reloading in the already clopidogrel-loaded patients undergo
Publikováno v:
The American Journal of Medicine. 132:e844-e845
Ranolazine is an anti-angina agent with many metabolites creating the potential for off-target effects. The U.S. Food and Drug Administration (FDA) reviews sometimes contain clinically relevant data not found in other sources.We reanalyzed data in an
Autor:
Makhabbat Bekbossynova, Marco Cattaneo, Victor L. Serebruany, Elena Z. Golukhova, Moo Hyun Kim, Yury Pya, Thomas A. Marciniak
Publikováno v:
International Journal of Cardiology. 215:273-276
Despite advanced techniques and improved clinical outcomes, the optimal antiplatelet strategy following coronary artery bypass grafting (CABG) is an unsolved mystery. Vorapaxar, a novel platelet thrombin receptor (PAR-1/4) blocker, is currently appro
Autor:
Victor L. Serebruany
Publikováno v:
International Journal of Cardiology. 201:508-512
After the successful PLATO, failed both PHILO and ATLANTIC, PEGASUS trial assessed efficacy and safety of ticagrelor (120 mg/day and 180 mg/day) on top of aspirin versus aspirin alone beyond 1 year in patients with stable coronary disease. Similar to
Publikováno v:
International Journal of Cardiology. 195:104-110
Background ST-elevated myocardial infarction (STEMI) holds the highest early mortality among patients with acute coronary syndromes. Despite numerous claims of clinical benefits and superiority over clopidogrel, there are no head-to-head outcome rand
Publikováno v:
The American Journal of Cardiology. 116:969-972
The impact of antithrombotics on cancer is currently under intense investigation because of the excess of solid cancers in trials after thienopyridines such as TRITON (prasugrel), DAPT (prasugrel and clopidogrel), PAR-1 thrombin antagonist in TRACER